Evaluating Disitamab vedotin for breast cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients diagnosed with breast cancer. Participants will include individuals who have either previously used or are currently using this treatment. The study will gather data on patient outcomes and side effects to better understand the drug's impact on breast cancer management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed breast cancer;
* Prior or current use of Disitamab vedotin (RC48-ADC);

Exclusion Criteria:

* Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.

Where it's running

• Renji Hospital, School of Medicine, Shanghai Jiaotong University
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Wenjin Yin, M.D. — Renji Hospital,School of Medicine, Shanghai Jiaotong University
• Study coordinator: Wenjin Yin, M.D.
• Email: yinwenjin@renji.com
• Phone: 86(21)68385569

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining Disitamab Vedotin with RC148 for treating HR-negative, HER2-low breast cancer

  This study is testing if a new combination of two treatments can help people with hard-to-treat HR-negative, HER2-low breast cancer feel better compared to standard options.

  Recruiting Phase 2 RemeGen Co., Ltd. · Beijing, Beijing Municipality · NCT06642545

• Evaluating a new treatment for HR-positive, HER2-low breast cancer

  This study is testing a new treatment combining Disitamab Vedotin and Toripalimab with chemotherapy to see if it helps people with HR-positive, HER2-low breast cancer before surgery.

  Recruiting Phase 2 RemeGen Co., Ltd. · Shanghai, Fudan University Shanghai Cancer Center · NCT06389006

• Neoadjuvant treatment for HR-negative, HER2 low-expressing breast cancer

  This study is testing a new combination treatment for people with HR-negative, HER2 low-expressing breast cancer to see if it helps them respond better than standard chemotherapy.

  Recruiting Phase 2 RemeGen Co., Ltd. · Changsha, Hunan and 4 other locations · NCT06227117

• Combination therapy for HER2-positive breast cancer

  This study tests a new combination of treatments for people with HER2-positive breast cancer to see if it helps them respond better before surgery.

  Recruiting Phase 2 RemeGen Co., Ltd. · Shanghai, Shanghai Municipality · NCT06178159

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.